Leandro Moreira
President of Transportation, Frontier Scientific Solutions
Breakthrough treatments such as advanced vaccines and gene therapies are transforming how diseases are treated or cured. However, these bring a new challenge: safely transporting highly sensitive medicines across the globe.
Unlike traditional pharmaceuticals, many modern medicines must be kept within strict temperature ranges throughout their journey from manufacturing sites to hospitals or pharmacies. Even small deviations in temperature or handling conditions can compromise product integrity, making reliable, controlled transportation essential. As pharmaceutical manufacturing has expanded globally, many logistics networks haven’t evolved at the same pace. Products often pass through multiple airports, warehouses and distribution centres before reaching patients, introducing risk, increasing dwell time and creating more opportunities for temperature excursions.
Creating solutions to better transport medicines globally
Frontier Scientific Solutions is among those building logistics infrastructure specifically designed for the life sciences industry, supporting both pharmaceutical manufacturers and the 3PL partners that manage their global distribution. Rather than adapting traditional cargo networks, Frontier Scientific Solutions’ approach integrates temperature- controlled storage, handling, distribution and air transport into a single, coordinated system designed to protect sensitive medicines at every stage of the journey. This model reflects the emergence of Qualified Temperature-Controlled Corridors, where each step in the supply chain operates within a single, aligned framework to reduce risk and maintain product integrity.
ensuring life-saving medicines move globally with the speed, control and reliability modern healthcare demands
Ireland’s role as a hub for pharmaceutical manufacturing
Ireland sits at the centre of the EU–US pharmaceutical manufacturing and supply chain ecosystem and is uniquely placed to bring together the expertise and knowledge required for pharmaceutical manufacturers to efficiently and compliantly deliver therapies across global markets. Building on this position, the Ireland–US corridor provides a more integrated and controlled approach to the movement of temperature-sensitive medicines between major global markets. Through this model, temperature-controlled storage, handling and transport are aligned to minimise handoffs, reduce dwell time and maintain consistent environmental conditions throughout transit — reducing complexity while ensuring products remain within tightly controlled parameters. For Ireland’s life sciences sector, one of the country’s most significant industries, efficient and reliable global logistics are critical. As medicines become more complex, higher value and increasingly temperature-sensitive, supply chains must evolve to ensure therapies reach patients quickly, safely and in full compliance.
By combining purpose-built infrastructure with specialised transportation networks and aligning stakeholders across a single, qualified corridor, this approach strengthens supply chain resilience and performance, ensuring life-saving medicines move globally with the speed, control and reliability modern healthcare demands. Breakthrough treatments such as advanced vaccines and gene therapies are transforming how diseases are treated and cured, but they also increase the need for highly controlled, end-to-end logistics capable of supporting these increasingly sensitive products at scale.
